ABL’s Bispecific Antibody For Parkinson's Lands In Sanofi’s Hands
$1bn Deal A CNS Leg Up For French Firm?
ABL Bio’s $1.06bn license deal with Sanofi for Parkinson's antibody is seen offering favorable terms to Korean biotech and is also poised to beef up French group’s presence in the space versus competitors.
